Plant-Derived and Endogenous Cannabinoids in Epilepsy

Alberto Verrotti, Miriam Castagnino, Mauro Maccarrone, Filomena Fezza

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalClinical Drug Investigation
DOIs
Publication statusAccepted/In press - Feb 18 2016

Fingerprint

Cannabinoids
Cannabis
Epilepsy
Psychotropic Drugs
Anticonvulsants
Seizures
Endocannabinoids
Partial Epilepsy
Drug and Narcotic Control
Smoke
Caregivers
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Plant-Derived and Endogenous Cannabinoids in Epilepsy. / Verrotti, Alberto; Castagnino, Miriam; Maccarrone, Mauro; Fezza, Filomena.

In: Clinical Drug Investigation, 18.02.2016, p. 1-10.

Research output: Contribution to journalArticle

Verrotti, Alberto ; Castagnino, Miriam ; Maccarrone, Mauro ; Fezza, Filomena. / Plant-Derived and Endogenous Cannabinoids in Epilepsy. In: Clinical Drug Investigation. 2016 ; pp. 1-10.
@article{9158464035a141bd8d8cc5d76560c5aa,
title = "Plant-Derived and Endogenous Cannabinoids in Epilepsy",
abstract = "Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.",
author = "Alberto Verrotti and Miriam Castagnino and Mauro Maccarrone and Filomena Fezza",
year = "2016",
month = "2",
day = "18",
doi = "10.1007/s40261-016-0379-x",
language = "English",
pages = "1--10",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Plant-Derived and Endogenous Cannabinoids in Epilepsy

AU - Verrotti, Alberto

AU - Castagnino, Miriam

AU - Maccarrone, Mauro

AU - Fezza, Filomena

PY - 2016/2/18

Y1 - 2016/2/18

N2 - Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.

AB - Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.

UR - http://www.scopus.com/inward/record.url?scp=84958765692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958765692&partnerID=8YFLogxK

U2 - 10.1007/s40261-016-0379-x

DO - 10.1007/s40261-016-0379-x

M3 - Article

SP - 1

EP - 10

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

ER -